Perioral Dermatitis
Conditions
Brief summary
A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis
Detailed description
This pilot study's intended purpose is to evaluate the efficacy, safety, and tolerability of sarecycline for periorificial dermatitis. Sarecycline, a third-generation tetracycline, is currently only indicated to treat acne vulgaris. However, the investigator has used sarecycline to treat periorificial dermatitis and would like to capture and report on this efficacy in a pilot study. The investigator hypothesize's that not only will the subjects respond well to sarecycline treatment, but that it will be well-tolerated.
Interventions
DRUGSeysara Oral Product
Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four.
Sponsors
The Dermatology Institute of Boston
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a single-center, prospective, pilot study to evaluate the efficacy, safety, and tolerability of sarecycline (Seysara) for periorificial dermatitis. This will be a four-week open-label study using sarecycline to treat POD.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Have a clinical diagnosis of POD by both the principal investigator and a blinded observer * Have a PODSI score of 3.0 or greater at baseline by clinical investigator * Must not be dysphagic. * Patient is male or female, 18-55 years of age inclusive at Screening.
Exclusion criteria
* Allergy to tetracyclines. * Immunocompromised. * Pregnancy or planning a pregnancy during the study period. * Lactating subjects. * Ongoing use of any of the following treatments to the face throughout study; oral or topical steroids, oral or topical calcineurin inhibitors, topical retinoids, topical antibiotics, - oral or topical metronidazole, or topical azelaic acid. * Facial hair or skin dermatoses that interfere with evaluation of the perioral dermatitis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PODSI score | 4 weeks | The PODSI represents the sum of individual scores for erythema, papules and scaling. Each of these key features is graded on a scale from 0 to 3 including intermediate values (0.5, 1.5 and 2.5). The PODSI is defined as the sum score of the 3 features, and may range from 0 to 9. All patients with a PODSI from 0.5 to 2.5 were regarded as mild, whereas severe cases scored with a PODSI from 6.0 to 9.0. All remaining patients with a PODSI from 3.0 to 5.5 were classified as moderate. |
Countries
United States
Outcome results
None listed